now offered by Bosch for Vivalytic Bosch’s Vivalytic Offers World’s First Automated PCR Test for Rapid Candida auris Detection at Point of Care

Bosch Healthcare Solutions Unveils World’s First Point-of-Care Test for Detecting Candida auris

Waiblingen, Germany – Bosch Healthcare Solutions has made a groundbreaking discovery in the field of healthcare with the development of a PCR test for detecting Candida auris (C. auris) on their Vivalytic platform. This test, now available for order through distribution partners Randox Laboratories Ltd. and R-Biopharm, is the first of its kind in the world, allowing for quick and accurate detection of the often multi-resistant fungus in less than an hour at the point of care.

The rapid testing capability of the Vivalytic C. auris test makes it suitable for screenings, providing a vital tool for hospitals to detect colonization and implement measures to contain outbreaks. With C. auris infection rates on the rise in Germany, this test is a crucial step in preventing severe infections, such as bloodstream infections (sepsis), in vulnerable patients.

Marc Meier, managing director of Bosch Healthcare Solutions, explains the importance of this innovation: “Considering the heightened risk of severe progression in individuals with pre-existing conditions, we have developed a new test that enables clinics to respond more swiftly.” Patients with compromised immune systems, such as those in intensive care, individuals with serious underlying conditions such as diabetes, or those who are immunosuppressed due to cancer or HIV, as well as patients about to undergo invasive surgery, face a heightened risk of active infection with C. auris. The mortality rate for C. auris infections ranges from 30 to 72 percent.

Dr. med. Alexander Maximilian Aldejohann, deputy head of the Würzburg Laboratory at the National Reference Center for Invasive Fungal Infections (NRZMyk), emphasizes the importance of rapid detection in controlling the spread of C. auris. “The fungus has the capacity to rapidly develop resistance to many common antifungal agents coupled with the ability to survive for a relatively long time on surfaces. This high so-called tenacity also increases the risk of outbreaks that are difficult to contain.”

C. auris is a global concern, with its spread increasing in countries such as the U.S. and Germany. The Centers for Disease Control and Prevention (CDC) in the U.S. have already recognized the importance of screening for C. auris in healthcare settings to curb its spread. The Vivalytic C. auris test provides an easy and efficient way to do so, with its fully automated process and minimal training requirements for healthcare professionals.

The Vivalytic Analyser enables effortless testing directly at the point of care, with the sample placed into the test cartridge and inserted into the analyzer for automated processing. CE certification for the Vivalytic C. auris test is expected soon.

Media contact:

Thomas Berroth

Marketing & Communication

+49 (0) 160 90437856

Distributed by

Share this article
Shareable URL
Prev Post

Erosion of Democratic Accountability Affects Majority of the World’s Population

Next Post

Health research underfunded, causing patients and society to suffer

Read next